Thomas Niel on Muck Rack

Thomas Niel

As seen in: Seeking Alpha, MSN, MSN Canada, Markets Insider, USA Today, Aol, Yahoo Finance, Substack, Flipboard, Nasdaq, The Motley Fool (U.S.) and
Value Investor Seeking Opportunities in Micro-cap and Nano-cap stocks. valueneversleeps.substack.com/
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Thomas

Contact Thomas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Amazon's Hidden Anthropic Stake Could Be Worth More Than Investors Realize

|
By Thomas Niel
| Yahoo Finance
Amazon (NASDAQ: AMZN) has many moving parts. For starters, there's the company's massive e-commerce business. Then, there's the company's main profit center, cloud computing giant Amazon Web Services (AWS). Amazon's advertising business is a powerhouse in the making as well. However, alongside these strong-performing segments is an equity position that could yield a 12-figure windfall.
Open in Who Shared View Duplicates (5) Issue with article?

Bristol Myers Squibb dividend raise streak is 18 years. Here's 1 number that says the streak will continue.

|
By Thomas Niel
| MSN
; ; ; Continue reading More for You Continue reading More for You
Open in Who Shared View Duplicates (296) Issue with article?

Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue. Original

|
By Thomas Niel
| The Motley Fool (U.S.)
Among healthcare stocks, Bristol Myers Squibb (BMY +2.88%) has built a solid track record of dividend growth. The pharmaceutical company has increased its quarterly dividends during each of the past 18 years. The company faces patent expirations for Eliquis and other flagship drugs, raising concerns that it can maintain (let alone grow) the dividend.
Open in Who Shared View Duplicates (4) Issue with article?
See all 3,411 licensed articles (3,413 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Thomas

Contact Thomas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified